CD274 and non-small cell lung carcinoma: In the first phase 3 trial reporting on the combination of CRT and ICI, patients with stage III non-small-cell lung cancer (NSCLC) were treated with CRT and sequentially received the PD-L1 inhibitor durvalumab or placebo.